Edward Coralde Banico
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edward Coralde Banico has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Fredmoore Legaspi Orosco
Industrial Technology Development Institute, Department of Science and Technology, Taguig, Philippines
6 shared publications - Ella Mae Joy S. Sira
Virology and Vaccine Research Program, Department of Science and Technology, Industrial Technology Development Institute, Taguig City, Philippines
4 shared publications - Nyzar Mabeth Obenio Odchimar
Virology and Vaccine Research Program, Department of Science and Technology, Industrial Technology Development Institute, Taguig City, Philippines
4 shared publications - Lauren Emily Fajardo
Virology and Vaccine Research Program, Department of Science and Technology, Industrial Technology Development Institute, Taguig City, Philippines
3 shared publications - Albert Neil Gura Dulay
Virology and Vaccine Research and Development Program, Department of Science and Technology-Industrial Technology Development Institute, Taguig City, Metro Manila 1631, Philippines
1 shared publication Alea Maurice Simbulan
Affiliation Department of Science and Technology, Virology and Vaccine Research Program, Industrial Development Technology Institute, Taguig City, Metro Manila, Philippines
1 shared publication
Latest Publications
- 1 August 2025
- Published by Springer Nature in Network Modeling Analysis in Health Informatics and Bioinformatics
- Vol. 14 (1) , 1-17
Reverse vaccinology-aided design of an epitope-based subunit vaccine against classical swine fever virus
- 1 August 2025
- Published by Springer Nature in Network Modeling Analysis in Health Informatics and Bioinformatics
- Vol. 14 (1) , 1-17
Reverse vaccinology-aided design of an epitope-based subunit vaccine against classical swine fever virus
- Open Access
- 30 June 2025
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 16 (3) , 236-251
Design and evaluation of a multi-epitope subunit vaccine against human norovirus using an immunoinformatics approach
Objectives: This study aimed to identify safe, conserved, and highly immunogenic epitopes from all proteins of human-infecting norovirus (NoV) and to design a multi-epitope subunit vaccine construct from these epitopes using an immunoinformatics approach. Additionally, the vaccine construct was evaluated using both sequence- and structure-based assessments.Methods: Conserved fragments were identified from all proteins of human-infecting NoV, and B and T lymphocyte epitopes were subsequently predicted using multiple epitope prediction tools. The selected epitopes were linked to form a multi-epitope construct, incorporating various adjuvants in the design. Vaccine constructs with different adjuvants were analyzed for their physicochemical properties and immune simulation profiles, and the optimal combination was selected as the final vaccine candidate for further study. Finally, molecular docking and dynamics simulations were performed to visualize the interaction between the construct and a host immune receptor.Results: Twenty-two safe, conserved, and highly immunogenic epitopes were identified from all human-infecting NoV proteins. The construct adjuvanted with 50S ribosomal protein L7/L12 (50SrpL7/L12) was chosen as the final vaccine candidate due to its optimal physicochemical properties and favorable immune simulation profile. Furthermore, the construct exhibited high binding affinity and a stable interaction with toll-like receptor 4).Conclusion: The multi-epitope subunit vaccine designed in this study shows promise as a potential NoV vaccine candidate for human immunization. Further in vitro and in vivo experiments are warranted to validate these findings.
- 30 June 2025
- Published by Korea Disease Control and Prevention Agency in Osong Public Health and Research Perspectives
- Vol. 16 (3) , 236-251
Open AccessDesign and evaluation of a multi-epitope subunit vaccine against human norovirus using an immunoinformatics approach
Objectives: This study aimed to identify safe, conserved, and highly immunogenic epitopes from all proteins of human-infecting norovirus (NoV) and to design a multi-epitope subunit vaccine construct from these epitopes using an immunoinformatics approach. Additionally, the vaccine construct was evaluated using both sequence- and structure-based assessments.Methods: Conserved fragments were identified from all proteins of human-infecting NoV, and B and T lymphocyte epitopes were subsequently predicted using multiple epitope prediction tools. The selected epitopes were linked to form a multi-epitope construct, incorporating various adjuvants in the design. Vaccine constructs with different adjuvants were analyzed for their physicochemical properties and immune simulation profiles, and the optimal combination was selected as the final vaccine candidate for further study. Finally, molecular docking and dynamics simulations were performed to visualize the interaction between the construct and a host immune receptor.Results: Twenty-two safe, conserved, and highly immunogenic epitopes were identified from all human-infecting NoV proteins. The construct adjuvanted with 50S ribosomal protein L7/L12 (50SrpL7/L12) was chosen as the final vaccine candidate due to its optimal physicochemical properties and favorable immune simulation profile. Furthermore, the construct exhibited high binding affinity and a stable interaction with toll-like receptor 4).Conclusion: The multi-epitope subunit vaccine designed in this study shows promise as a potential NoV vaccine candidate for human immunization. Further in vitro and in vivo experiments are warranted to validate these findings.
- 30 April 2025
- Published by Philippine-American Academy of Science and Engineering in SciEnggJ
- Vol. 18 (1) , 82-101
n silico approach for designing a pan-proteomic and pan-genotypic hepatitis C virus multi-epitope subunit vaccine
Hepatitis C Virus (HCV) is the most infectious hepatitis virus and the leading cause of liver-related mortality. The lack of a vaccine, combined with HCV’s hypervariability, contributes to this global health concern; thus, there is an urgent need for a potent, cross-protective vaccine. With the aid of computational vaccinology, we aimed to design and evaluate multi-epitope vaccines based on highly conserved epitopes from multiple proteins across 8 recognized HCV genotypes and 47 subtypes. The designed HCV vaccine constructs (VC) are composed of antigenic, non-allergenic, non-toxic, non-human homologues, and conserved epitopes within the structural and non-structural HCV proteins, linked with proper adjuvants and linkers. The final HCV VC had an instability index of 33.69. Tertiary structure validation of the modelled HCV VC revealed a high-quality protein. Molecular docking, molecular dynamic simulations, and Molecular Mechanics/Poisson–Boltzmann Surface Area (MM/PBSA) and General Born Surface Area (MM/GBSA) calculations demonstrated a strong and stable binding interaction between the HCV VC and immune receptors (TLR2, 3, and 4). The final HCV VC-TLR3 is the best docking complex (-226.61 kcal/mol) with a highly stable binding affinity in the entire 200 ns molecular dynamics simulation. Notably, immune simulation revealed that HCV VC elicited a high antibody level and stronger IFN-ɣ and IL-2 levels compared to reference studies. This study designed a novel multi-epitope HCV VC that could provide a stronger immune response and cross-protection against hypervariable HCV that requires further in vitro validation.
- 30 April 2025
- Published by Philippine-American Academy of Science and Engineering in SciEnggJ
- Vol. 18 (1) , 82-101
n silico approach for designing a pan-proteomic and pan-genotypic hepatitis C virus multi-epitope subunit vaccine
Hepatitis C Virus (HCV) is the most infectious hepatitis virus and the leading cause of liver-related mortality. The lack of a vaccine, combined with HCV’s hypervariability, contributes to this global health concern; thus, there is an urgent need for a potent, cross-protective vaccine. With the aid of computational vaccinology, we aimed to design and evaluate multi-epitope vaccines based on highly conserved epitopes from multiple proteins across 8 recognized HCV genotypes and 47 subtypes. The designed HCV vaccine constructs (VC) are composed of antigenic, non-allergenic, non-toxic, non-human homologues, and conserved epitopes within the structural and non-structural HCV proteins, linked with proper adjuvants and linkers. The final HCV VC had an instability index of 33.69. Tertiary structure validation of the modelled HCV VC revealed a high-quality protein. Molecular docking, molecular dynamic simulations, and Molecular Mechanics/Poisson–Boltzmann Surface Area (MM/PBSA) and General Born Surface Area (MM/GBSA) calculations demonstrated a strong and stable binding interaction between the HCV VC and immune receptors (TLR2, 3, and 4). The final HCV VC-TLR3 is the best docking complex (-226.61 kcal/mol) with a highly stable binding affinity in the entire 200 ns molecular dynamics simulation. Notably, immune simulation revealed that HCV VC elicited a high antibody level and stronger IFN-ɣ and IL-2 levels compared to reference studies. This study designed a novel multi-epitope HCV VC that could provide a stronger immune response and cross-protection against hypervariable HCV that requires further in vitro validation.
- Open Access
- 3 January 2025
- Published by Wiley in Veterinary Medicine International
- Vol. 2025 (1) , 2638167
Design of a Multiepitope Pan‐Proteomic mRNA Vaccine Construct Against African Swine Fever Virus: A Reverse Vaccinology Approach
African swine fever (ASF), caused by African swine fever virus (ASFV), is a highly contagious disease with devastating effects on the global pig industry. This warrants the development of effective control strategies, such as vaccines. However, previously developed inactivated vaccines have proven ineffective, while live‐attenuated vaccines carry inherent safety risks. The use of mRNA vaccines eliminates these risks offering a safe, cost‐effective, and efficient vaccine strategy against ASFV. In this study, a reverse vaccinology approach was used to design a multiepitope pan‐proteomic mRNA vaccine against ASFV. Various bioinformatics tools were employed to predict epitopes for cytotoxic T lymphocytes, helper T lymphocytes, and B lymphocytes. A 50S ribosomal L7/L12 protein adjuvant, 5′ cap, poly(A) tail, signal peptide, and MHC‐I‐targeting domain were incorporated into the design using appropriate linkers to increase immunogenicity, stability, and recognition efficiency. The physicochemical properties of the final construct were evaluated, and docking analyses were done with Toll‐like receptors (TLRs) 3, 4, and 7 to evaluate binding affinity. A molecular dynamics simulation was then performed to determine binding stability, while immune simulations evaluated host’s immune response. Based on 100 ASFV proteomes, six epitopes that induce cytotoxic T‐cell responses, five epitopes that induce helper T‐cell responses, and four epitopes that induce antibody production were predicted. The designed vaccine construct was found to be nonallergenic, antigenic, and stable when bound to TLR4 while the binding pocket analyses of the vaccine construct to TLR3 and TLR7 indicate high translation efficiency. Immune simulations demonstrated successful induction of immune responses and generation of antigen‐specific memory cells. In conclusion, this study introduces an mRNA vaccine construct as a potential disease control strategy against ASF for in vitro confirmation.
- 3 January 2025
- Published by Wiley in Veterinary Medicine International
- Vol. 2025 (1) , 2638167
Open AccessDesign of a Multiepitope Pan‐Proteomic mRNA Vaccine Construct Against African Swine Fever Virus: A Reverse Vaccinology Approach
African swine fever (ASF), caused by African swine fever virus (ASFV), is a highly contagious disease with devastating effects on the global pig industry. This warrants the development of effective control strategies, such as vaccines. However, previously developed inactivated vaccines have proven ineffective, while live‐attenuated vaccines carry inherent safety risks. The use of mRNA vaccines eliminates these risks offering a safe, cost‐effective, and efficient vaccine strategy against ASFV. In this study, a reverse vaccinology approach was used to design a multiepitope pan‐proteomic mRNA vaccine against ASFV. Various bioinformatics tools were employed to predict epitopes for cytotoxic T lymphocytes, helper T lymphocytes, and B lymphocytes. A 50S ribosomal L7/L12 protein adjuvant, 5′ cap, poly(A) tail, signal peptide, and MHC‐I‐targeting domain were incorporated into the design using appropriate linkers to increase immunogenicity, stability, and recognition efficiency. The physicochemical properties of the final construct were evaluated, and docking analyses were done with Toll‐like receptors (TLRs) 3, 4, and 7 to evaluate binding affinity. A molecular dynamics simulation was then performed to determine binding stability, while immune simulations evaluated host’s immune response. Based on 100 ASFV proteomes, six epitopes that induce cytotoxic T‐cell responses, five epitopes that induce helper T‐cell responses, and four epitopes that induce antibody production were predicted. The designed vaccine construct was found to be nonallergenic, antigenic, and stable when bound to TLR4 while the binding pocket analyses of the vaccine construct to TLR3 and TLR7 indicate high translation efficiency. Immune simulations demonstrated successful induction of immune responses and generation of antigen‐specific memory cells. In conclusion, this study introduces an mRNA vaccine construct as a potential disease control strategy against ASF for in vitro confirmation.
- Open Access
- 4 November 2024
- Published by Veterinary World in International Journal of One Health
Bridging One Health: Computational design of a multi-epitope messenger RNA vaccine for cross-species immunization against Nipah virus
Background and Aim: Nipah virus (NiV) poses a threat to human and animal health, particularly swine, which serve as primary vectors for human transmission. Despite its severe risks, no NiV vaccine currently exists for humans or animal hosts; thus, innovative vaccine development approaches that address cross-species transmission are required. This study was computationally designed to evaluate a multi-epitope messenger RNA (mRNA) vaccine targeting NiV for human and swine immunization. Materials and Methods: B and T lymphocyte epitopes were identified from NiV structural proteins using multiple epitope prediction tools. All epitopes were linked to form a multi-epitope construct, and various adjuvant combinations were analyzed for physicochemical properties and immune simulation. Molecular docking and dynamics were employed to visualize the construct’s interaction with a host immune receptor. Signal peptides were added to the construct, and mRNA sequences were generated using LinearDesign. The minimum free energies (MFEs) and codon adaptation indices (CAI) were used to select the final mRNA sequence of the vaccine construct. Results: Computational tools predicted 10 epitopes within NiV structural proteins that can be recognized by human and swine immune receptors. The construct with β-defensin 2 adjuvant was selected as the final immunogenic region after showing favorable immunogenicity profiles and physicochemical properties. The final vaccine sequence had higher MFE and CAI compared to the BioNTech/Pfizer BNT162b2 and Moderna mRNA-1273 vaccines. Conclusion: The multi-epitope mRNA vaccine designed in this study shows promising results as a potential NiV vaccine candidate. Further in vivo and in vitro studies are required to confirm the efficacy. Keywords: computational design, cross-species immunization, messenger RNA vaccine, multi-epitope, Nipah virus.
- 4 November 2024
- Published by Veterinary World in International Journal of One Health
Open AccessBridging One Health: Computational design of a multi-epitope messenger RNA vaccine for cross-species immunization against Nipah virus
Background and Aim: Nipah virus (NiV) poses a threat to human and animal health, particularly swine, which serve as primary vectors for human transmission. Despite its severe risks, no NiV vaccine currently exists for humans or animal hosts; thus, innovative vaccine development approaches that address cross-species transmission are required. This study was computationally designed to evaluate a multi-epitope messenger RNA (mRNA) vaccine targeting NiV for human and swine immunization. Materials and Methods: B and T lymphocyte epitopes were identified from NiV structural proteins using multiple epitope prediction tools. All epitopes were linked to form a multi-epitope construct, and various adjuvant combinations were analyzed for physicochemical properties and immune simulation. Molecular docking and dynamics were employed to visualize the construct’s interaction with a host immune receptor. Signal peptides were added to the construct, and mRNA sequences were generated using LinearDesign. The minimum free energies (MFEs) and codon adaptation indices (CAI) were used to select the final mRNA sequence of the vaccine construct. Results: Computational tools predicted 10 epitopes within NiV structural proteins that can be recognized by human and swine immune receptors. The construct with β-defensin 2 adjuvant was selected as the final immunogenic region after showing favorable immunogenicity profiles and physicochemical properties. The final vaccine sequence had higher MFE and CAI compared to the BioNTech/Pfizer BNT162b2 and Moderna mRNA-1273 vaccines. Conclusion: The multi-epitope mRNA vaccine designed in this study shows promising results as a potential NiV vaccine candidate. Further in vivo and in vitro studies are required to confirm the efficacy. Keywords: computational design, cross-species immunization, messenger RNA vaccine, multi-epitope, Nipah virus.
- Open Access
- 26 September 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (9) , e0310703
Advancing one health vaccination: In silico design and evaluation of a multi-epitope subunit vaccine against Nipah virus for cross-species immunization using immunoinformatics and molecular modeling
The resurgence of the Nipah virus (NiV) in 2023 has raised concerns for another potentially severe pandemic, given its history of high mortality from previous outbreaks. Unfortunately, no therapeutics and vaccines have been available for the virus. This study used immunoinformatics and molecular modeling to design and evaluate a multi-epitope subunit vaccine targeting NiV. The designed vaccine construct aims to stimulate immune responses in humans and two other intermediate animal hosts of the virus—swine and equine. Using several epitope prediction tools, ten peptides that induced B-lymphocyte responses, 17 peptides that induced cytotoxic T-lymphocyte (CTL) responses, and 12 peptides that induced helper T-lymphocyte (HTL) responses were mapped from nine NiV protein sequences. However, the CTL and HTL-inducing peptides were reduced to ten and eight, respectively, following molecular docking and dynamics. These screened peptides exhibited stability with 30 common major histocompatibility complex (MHC) receptors found in humans, swine, and equine. All peptides were linked using peptide linkers to form the multi-epitope construct and various adjuvants were tested to enhance its immunogenicity. The vaccine construct with resuscitation-promoting factor E (RpfE) adjuvant was selected as the final design based on its favorable physicochemical properties and superior immune response profile. Molecular docking was used to visualize the interaction of the vaccine to toll-like receptor 4 (TLR4), while molecular dynamics confirmed the structural stability of this interaction. Physicochemical property evaluation and computational simulations showed that the designed vaccine construct exhibited favorable properties and elicited higher antibody titers than the six multi-epitope NiV vaccine designs available in the literature. Further in vivo and in vitro experiments are necessary to validate the immunogenicity conferred by the designed vaccine construct and its epitope components. This study demonstrates the capability of computational methodologies in rational vaccine design and highlights the potential of cross-species vaccination strategies for mitigating potential NiV threats.
- 26 September 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (9) , e0310703
Open AccessAdvancing one health vaccination: In silico design and evaluation of a multi-epitope subunit vaccine against Nipah virus for cross-species immunization using immunoinformatics and molecular modeling
The resurgence of the Nipah virus (NiV) in 2023 has raised concerns for another potentially severe pandemic, given its history of high mortality from previous outbreaks. Unfortunately, no therapeutics and vaccines have been available for the virus. This study used immunoinformatics and molecular modeling to design and evaluate a multi-epitope subunit vaccine targeting NiV. The designed vaccine construct aims to stimulate immune responses in humans and two other intermediate animal hosts of the virus—swine and equine. Using several epitope prediction tools, ten peptides that induced B-lymphocyte responses, 17 peptides that induced cytotoxic T-lymphocyte (CTL) responses, and 12 peptides that induced helper T-lymphocyte (HTL) responses were mapped from nine NiV protein sequences. However, the CTL and HTL-inducing peptides were reduced to ten and eight, respectively, following molecular docking and dynamics. These screened peptides exhibited stability with 30 common major histocompatibility complex (MHC) receptors found in humans, swine, and equine. All peptides were linked using peptide linkers to form the multi-epitope construct and various adjuvants were tested to enhance its immunogenicity. The vaccine construct with resuscitation-promoting factor E (RpfE) adjuvant was selected as the final design based on its favorable physicochemical properties and superior immune response profile. Molecular docking was used to visualize the interaction of the vaccine to toll-like receptor 4 (TLR4), while molecular dynamics confirmed the structural stability of this interaction. Physicochemical property evaluation and computational simulations showed that the designed vaccine construct exhibited favorable properties and elicited higher antibody titers than the six multi-epitope NiV vaccine designs available in the literature. Further in vivo and in vitro experiments are necessary to validate the immunogenicity conferred by the designed vaccine construct and its epitope components. This study demonstrates the capability of computational methodologies in rational vaccine design and highlights the potential of cross-species vaccination strategies for mitigating potential NiV threats.